. "OBJECTIVES: Arterial stiffening and endothelial dysfunction are hallmarks of aging, and advanced glycation endproducts (AGE) may contribute to these changes. We tested the hypothesis that AGE crosslink breakers enhance endothelial flow-mediated dilation (FMD) in humans and examined the potential mechanisms for this effect. METHODS: Thirteen adults (nine men, aged 65 +/- 2 years) with isolated systolic hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure < 90 mmHg or pulse pressure > 60 mmHg) on stable antihypertensive therapy were studied. Subjects received placebo (2 weeks) then oral alagebrium (ALT-711; 210 mg twice a day for 8 weeks). Subjects and data analyses were blinded to treatment. Arterial stiffness was assessed by carotid augmentation index (AI) and brachial artery distensibility (ArtD) using applanation tonometry and Doppler echo, and endothelial function by brachial FMD. Serum markers of collagen metabolism and vascular inflammation were asse" . "408648" . "Journal of Hypertension" . "3" . . . "7"^^ . "Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension" . "cardiology"@en . "Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension"@en . "Kass, D. A." . . . . "[FC287222E004]" . "Capriotti, A." . . "Zieman, S. J." . "25" . . "Coretti, M. C." . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "7"^^ . "577-583" . . "Melenovsk\u00FD, Vojt\u011Bch" . "Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension" . "%22Crosslink breaker%22 (dosl. ni\u010Ditel p\u0159\u00ED\u010Dn\u00E9 vazby) koncov\u00E9ho produktu pokro\u010Dil\u00E9 glykace (alagebrium) zlep\u0161uje u pacient\u016F s izolovanou systolickou hypertenz\u00ED funkci endotelu"@cs . "Gerstenblith, G." . "RIV/00023001:_____/07:00001574!RIV08-MZ0-00023001" . "0263-6352" . . "RIV/00023001:_____/07:00001574" . "OBJECTIVES: Arterial stiffening and endothelial dysfunction are hallmarks of aging, and advanced glycation endproducts (AGE) may contribute to these changes. We tested the hypothesis that AGE crosslink breakers enhance endothelial flow-mediated dilation (FMD) in humans and examined the potential mechanisms for this effect. METHODS: Thirteen adults (nine men, aged 65 +/- 2 years) with isolated systolic hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure < 90 mmHg or pulse pressure > 60 mmHg) on stable antihypertensive therapy were studied. Subjects received placebo (2 weeks) then oral alagebrium (ALT-711; 210 mg twice a day for 8 weeks). Subjects and data analyses were blinded to treatment. Arterial stiffness was assessed by carotid augmentation index (AI) and brachial artery distensibility (ArtD) using applanation tonometry and Doppler echo, and endothelial function by brachial FMD. Serum markers of collagen metabolism and vascular inflammation were asse"@en . "Clattenburg, L." . "N" . "%22Crosslink breaker%22 (dosl. ni\u010Ditel p\u0159\u00ED\u010Dn\u00E9 vazby) koncov\u00E9ho produktu pokro\u010Dil\u00E9 glykace (alagebrium) zlep\u0161uje u pacient\u016F s izolovanou systolickou hypertenz\u00ED funkci endotelu"@cs . "1"^^ . . "tuhnut\u00ED tepenn\u00E9 st\u011Bny, endoteli\u00E1ln\u00ED dysfunkce, st\u00E1rnut\u00ED, koncov\u00E9 produky pokro\u010Dil\u00E9 glykace"@cs . . "Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension"@en .